regardless of positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant difficulty from managed care entities. The insurers are typically creating barriers to reimbursement, like significant cost requirements and PA that limit consumer opportunity. Analysts believe th